ZUSAMMENFASSUNG Hintergrund:
Bei der Leberzirrhose trägt ein erhöhter intrahepatischer 
INTRODUCTION
Increased resistance to portal blood flow is a primary factor in the pathophysiology of portal hypertension [1] [2] [3] [4] . Anatomical abnormalities-such as narrowing of intrahepatic microvessels because of fibrosis-are a major cause of the increased resistance to portal flow. However, a dynamic component caused by an abnormally active contraction of the hepatic microvasculature plays an additional role in the development of increased intrahepatic resistance [5, 6] . This part of the intrahepatic resistance to portal flow is regulated by intrahepatic portal venules and hepatic stellate cells (HSCs) [7, 8] . Decreased formation and action of the vasodilator nitric oxide in the hepatic vascular bed supports the presence of portal hypertension [5, [9] [10] [11] [12] [13] [14] [15] [16] . Furthermore, the intrahepatic resistance of cirrhotic livers shows hyperresponsiveness to vasoconstrictors such as noradrenaline (norepinephrine) and endothelin [5, 6, [17] [18] [19] [20] [21] [22] .
The RhoA/Rho-kinase pathway is essentially involved in vasoconstriction and the regulation of vascular tone [23] [24] [25] [26] [27] [28] [29] [30] . The pathway is activated by contractile agonists through G-protein coupled vasopressor receptors (fig 1) . These receptors activate the small monomeric GTPase, RhoA. Thereafter, RhoA activates Rho-kinase, which subsequently inhibits myosin-light-chain-phosphatase (MLC-phosphatase). Inhibition of MLC-phosphatase results in enhanced phosphorylation of MLCs and contraction. Although it has been reported that RhoA is expressed in activated HSCs and that the RhoA/Rho-kinase pathway plays an important role in HSC activation and hepatic fibrogenesis [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] , the actions of this pathway in the regulation of intrahepatic resistance to portal blood flow remain unknown. We therefore studied the role of the RhoA/Rho-kinase pathway in the intrahepatic vascular resistance of rats with secondary biliary cirrhosis and investigated whether it is involved in the pathogenesis of portal hypertension.
METHODS

Animals
Male Sprague-Dawley rats (180 to 200 g) were obtained from Charles River Laboratories (Sulzfeld, Germany) and maintained on standard chow on a 12 hour light/dark cycle. The rats were randomly divided into two groups. In one group, bile duct ligation was carried out as previously described [42] . Briefly, rats were anaesthetized with ketamine hydrochloride (100 mg/kg); the common bile duct was exposed by an upper abdominal midline incision of 1.5 cm and was ligated twice with 5-0 silk suture and resected between the ligatures; muscle and skin were sutured separately with 3-0 silk. The rats of the other group were sham operated and served as controls. These animals therefore experienced the same procedures except that the bile duct was manipulated but not ligated and sectioned.
The study was approved by the local committee for animal studies (administrative authority, Cologne, Germany, 50.203-Bn 15, 23/03).
Patients
Samples of liver tissue from patients with alcohol induced cirrhosis (n = 3) were obtained during liver transplantation. Non-tumour-bearing liver tissue obtained during resection of liver malignancies served as normal control (n = 3). The use of human liver specimens was approved by the local ethics committee.
Western blot analysis
Samples of shock frozen livers were homogenized in a buffer containing 25 
Quantitative real time reverse transcription polymerase chain reaction
RNA was isolated from 30 mg shock frozen liver tissue using the RNeasy-mini kit (Qiagen, 
Assessment of Rho-kinase activity
Rho-kinase activity was assessed as phosphorylation of the endogenous Rho-kinase substrate, moesin, at thr-558 [43] [44] [45] [46] [47] [48] . This was done by western blot analysis using a site specific and phosphospecific anti-moesin antibody (Santa Cruz Biotechnology). In parallel, total moesin was analysed using a non-phosphospecific antibody (Santa Cruz Biotechnology).
Immunohistochemistry
Immunohistochemical staining of liver sections was carried out using the indirect immunoperoxidase technique as previously described [49] with the exception that the incubation with the primary antibody (site specific and phosphospecific anti-moesin antibody) was prolonged (overnight), and a swine anti-rabbit antibody (Dako, Carpinteria, California, USA) was used as secondary antibody.
In situ liver perfusion
In situ liver perfusion was carried out in a recirculating system according to a previously described technique [9] . Briefly, rats were fasted overnight but allowed free access to water.
Only cirrhotic rats with ascites were included in the study. After being anaesthetised with ketamine hydrochloride (60 mg/kg), the abdomen was opened and the bile duct was cannulated with a polyethyl tube to monitor bile flow. Loose ligatures were placed around portal vein, common hepatic artery, spleen vein, and posterior vena cava just cranially to the confluence of the right renal vein. A 500 U dose of heparin was injected into the posterior vena cava. The portal vein was cannulated with a 14-gauge Teflon catheter, initiating liver exsanguinations by infusion (30 ml/min) of Krebs-Henseleit solution containing heparin (2 U/ml) and oxygenated with carbogen (95% O 2 , 5% CO 2 ). The posterior vena cava was immediately cut caudally to the loose ligature, allowing the perfusate to escape. Thereafter, the thorax was opened and the right atrium was cut.
Another catheter was introduced in the right atrium and pushed forward to the inferior vena cava. Next, all ligatures were pulled tight. At a constant flow (30 ml/min), perfusion pressure was monitored continuously and recorded digitally on-line. The preparation was allowed to stabilize for 20 minutes without any procedure.
Viability and stability of liver perfusion preparation
The criteria for liver viability included gross appearance of the liver, stable perfusion, bile production >0.4 μl/min*g, and stable buffer pH (7.4±0.1) during the initial 20 minute stabilization period. If one of the viability criteria was not met, the experiment was discarded.
Effect of the α1 adrenoceptor agonist methoxamine on portal perfusion pressure
In one set of experiments, livers were initially perfused at a constant flow (30 ml/min) for a period of 20 minutes without any procedure in order to stabilize the entire system. Then cumulative concentration-response curves with the α 1 adrenoceptor agonist methoxamine (0.1 μM to 100 μM) were obtained by addition of the agonist to the perfusate. Changes in perfusion pressure were expressed either as the absolute perfusion pressure after administration of methoxamine, or as change in perfusion pressure elicited by the given concentration of methoxamine in the perfusate (that is, perfusion pressure minus basal pressure).
Effect of the Rho-kinase inhibitor Y-27632 on methoxamine induced hepatic flow resistance
In another set of experiments, 10 minutes before addition of the first dose of methoxamine, Y-27632 was added to the perfusate in different concentrations (1, 10, and 30 μM).
Thereafter, cumulative concentration-response curves for methoxamine were constructed as described above.
Haemodynamic studies
Haemodynamic studies were carried out under ketamine anaesthesia (60 mg/kg intravenously). This condition has been shown to approximate most closely the conscious state in terms of cardiac output and regional blood flow and has been used extensively to investigate the haemodynamic effects of portal pressure lowering drugs in animal models of portal hypertension [2, 42, 50, 51] . The left femoral artery and vein were cannulated with PE-50 catheters for measurement of arterial pressure and blood withdrawal, as well as for drug infusion. Median laparotomy was carried out and a PE-50 catheter was introduced into a small ileocaecal vein and advanced to the confluence of the portal and splenic vein for the measurement of portal pressure. Through the right carotid artery another PE-50
catheter was advanced into the left ventricle under pulse curve control. This catheter was used for microsphere application. The catheters in the femoral artery and the portal vein were connected to pressure transducers (Hugo Sachs Electronic, March-Hugstetten, Germany) for blood pressure measurement. The zero point was 1 cm above the operating table.
Regional blood flows were measured using the coloured microsphere method, as previously described [42, 52] . A reference sample was obtained for one minute at a rate of 0.65 ml/min using a continuous withdrawal pump (Hugo Sachs Electronic). Then 300 000 yellow microspheres ( Porto-systemic shunting (PSS) was estimated as previously described, after the injection of 150 000 blue microspheres in 0.3 ml saline containing 0.05% Tween into an ileocaecal vein within 30 seconds [42, 53] . The tissue microsphere content was calculated as described for the measurement of organ blood flow. PSS was calculated as the number of microspheres in the lungx100 divided by the number of microspheres in lung and liver. Portal venous inflow (PVI) was calculated as the sum of the blood flows to stomach, spleen, intestines, pancreas, and mesentery. Collateral blood flow (ml/minx100 g) was estimated as PVIxPSS/100. Vascular resistances were calculated from the ratio between perfusion pressure and blood flow of each vascular territory.
Statistical analysis
Data are presented as means (SEM) with the indicated number (n) of experiments. 
Analysis
RESULTS
Hepatic expression of RhoA and Rho-kinase
Western blot analysis of whole liver homogenates showed a strong upregulation of RhoA and Rho-kinase protein levels in livers from BDL rats compared with sham operated rats (fig 2A) . In parallel, as revealed by quantitative RT-PCR with mRNA isolated from whole liver homogenates, both RhoA and Rho-kinase mRNA were significantly raised in livers from sham operated and BDL rats ( fig 2B) . mRNA expression, data from quantitative reverse transcription polymerase chain reaction. Shown are mRNA levels in whole liver homogenates from both groups (sham n = 7, BDL n = 6). d.u., densitometric units.
Hepatic moesin phosphorylation
Phosphorylation of moesin-a marker for Rho-kinase activity [43] [44] [45] [46] [47] [48] was greatly increased in livers of BDL rats ( fig 3A) . This difference was not associated with changes in total moesin, which was similar in both groups ( fig 3A) . As thr-558 of moesin is preferentially phosphorylated by Rho-kinase, these findings probably reflect an increased basal Rho-kinase activity in livers of BDL rats.
To localize the sites of intrahepatic moesin hyperphosphorylation in BDL rats, immunohistochemical investigations for phospho-moesin were undertaken in liver sections from sham operated and BDL rats. Phosphorylated moesin was highly present within the walls of the intrahepatic branches of portal venules and hepatic arteries (fig 4) . The staining for phospho-moesin within these vessel walls was significantly stronger in BDL rats than in sham operated rats, and to some degree in the hepatic arteries (fig 4) . In contrast, no phospho-moesin was detected in the remaining intrahepatic sites (hepatocytes or extracellular space), and only weak staining in the perisinusoidal cells (fig 4) .
The phosphorylation state of moesin was also investigated by western blot analysis in human livers (whole liver homogenates from cirrhotic v non-cirrhotic patients). These experiments showed a clear trend towards raised phospho-moesin levels in livers from cirrhotic patients (alcohol induced cirrhosis) when compared with those from non-cirrhotic patients ( fig 3B) . 
Basal intrahepatic resistance and modulation by Rho-kinase inhibition
At a constant flow, changes in perfusion pressure reflect changes in intrahepatic resistance.
In BDL rats, the perfusion pressure of in situ perfused livers was on average increased threefold ( fig 5A) . In order to assess whether increased hepatic expression and activity of Rho-kinase is related to intrahepatic vascular resistance, we tested the effect of the 
Effect of Rho-kinase inhibition on methoxamine induced increase in intrahepatic resistance
To investigate the role of the RhoA/Rho-kinase pathway in vasoconstrictor mediated regulation of intrahepatic microvascular tone, we studied the effect of Y-27632 on the methoxamine induced increase in intrahepatic perfusion pressure. As shown in fig 6A, the addition of methoxamine to the perfusate elicited dose dependent increases in perfusion pressure in both groups. The sensitivity of livers from BDL rats to methoxamine was significantly greater than in sham operated rats, as shown by the increase in EC 50 (fig 6C, left columns). This underlines the well known hyperreactivity of the hepatic vascular resistance of cirrhotic livers to vasoconstrictors. However, the changes in perfusion pressure (P max ) elicited by the maximum concentration of methoxamine (100 μM) were similar in both groups (fig 6, A and D, left panels) , although the perfusion pressures reached in BDL rats were higher than in sham operated rats, owing to the higher basal intrahepatic perfusion pressure. 
Haemodynamic in vivo effects of Rho-kinase inhibition
To obtain further insight into the regulation of portal pressure through the RhoA/Rho-kinase pathway in vivo, we studied the haemodynamic effects of bolus injection of different doses of Y-27632.
As expected, BDL rats had increased portal pressure, low arterial pressure, decreased splanchnic vascular resistance, increased intrahepatic resistance, and increased porto-systemic shunt flow. Bolus injection of Y-27632 (0.1 mg/kg) reduced portal pressure in BDL but not in sham operated rats ( fig 7A) . Interestingly, this was paralleled by a significant decrease in hepatic vascular resistance in BDL rats but not in sham operated rats ( fig 8A) . In contrast, splanchnic vascular resistance and hepatic arterial flow were unaffected in BDL rats, but reduced in sham operated rats after bolus injection of 0.1 mg/kg Y-27632 (fig 7, panels C and D) . The shunt volume in BDL rats was significantly increased after Y-27632 ( fig 8B) . In both groups, the systemic administration of 0.1 mg/kg Y-27632 did not change mean arterial pressure ( fig 7B) . Bolus injection of Y-27632 in a dose of 1 mg/kg elicited large and sustained decreases in portal pressure in BDL rats but had no effect on portal pressure in sham operated rats ( fig 7A) . The reduction in portal pressure in response to the high dose of Y-27632 was associated with a further reduction in hepatic vascular resistance (but also with further increases in portal venous inflow and shunt volume) in BDL rats, but not in sham operated rats (fig 8) . Therefore, we investigated the RhoA/Rho-kinase pathway in the vasoconstrictor mediated intrahepatic regulation of liver blood flow. It has been shown that this pathway is essentially involved in contraction of vascular smooth muscle [23] [24] [25] [26] [27] [28] [29] [30] . Furthermore, a role for RhoA/Rho-kinase mediated signalling in activation and contraction of hepatic stellate cells as well as in hepatic fibrogenesis has also been demonstrated [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] . Rho-kinase signalling also contribute to the increased hepatic vascular resistance in other models of cirrhosis of the liver. As an increase in moesin phosphorylation was also found in livers from patients with alcohol induced cirrhosis, it seems possible that the Rho-kinase mediated increase in hepatic vascular resistance is not restricted to biliary cirrhosis in rats, but is rather a common feature of cirrhosis of the liver. Arterial pressure and splanchnic vascular resistance were also reduced by Y-27632. However, at the lower dose, Y-27632 reduced portal pressure in BDL rats without affecting arterial pressure. Thus most of the portal pressure lowering effect of Y-27632 seems to be mediated by decreasing intrahepatic resistance. Nevertheless, liver-specific drugs inhibiting the RhoA/Rho-kinase signaling preferentially in the cirrhotic liver should be developed before testing such drugs for pharmacological treatment of portal hypertension. Such Rho-kinase inhibiting drugs have the advantage that they also decrease hepatic fibrogenesis [38] [39] [40] [41] .
In summary, increased intrahepatic resistance in rats with secondary biliary cirrhosis is associated with an upregulation of RhoA and Rho-kinase signalling. Inhibition of this pathway in the liver can reduce portal pressure in rats with secondary biliary cirrhosis.
